Stati Uniti - Ingliż - NLM (National Library of Medicine)

avkare, inc. - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 10 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

cardinal health - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 20 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

avpak - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 10 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

kaiser foundation hospitals - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 10 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 20 mg - therapy with lovastatin tablets usp should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. lovastatin tablets usp should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-c and ldl-c to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. primary prevention of coronary heart disease in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c and below average hdl-c, lovastatin tablets usp are indicated to reduce the risk of: -myocardial infarction -unstable angina -coronary revascularization procedures (see clinical pharmacology, clinical studies). coronary heart disease lovastatin tablets usp are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower

Stati Uniti - Ingliż - NLM (National Library of Medicine)

remedyrepack inc. - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 40 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - therapy with lovastatin tablets usp should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. lovastatin tablets usp should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-c and ldl-c to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c, lovastatin tablets usp are indicated to reduce the risk of: - myocardial infarction - unstable angina - coronary revascularization procedures (see clinical pharmacology, clinical studies ) lovastatin tablets usp are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target levels. therapy with lipid-altering a

Kanada - Ingliż - Health Canada

mylan pharmaceuticals ulc - lovastatin - tablet - 20mg - lovastatin 20mg - hmg-coa reductase inhibitors

Kanada - Ingliż - Health Canada

mylan pharmaceuticals ulc - lovastatin - tablet - 40mg - lovastatin 40mg - hmg-coa reductase inhibitors

Kanada - Ingliż - Health Canada

pharmascience inc - lovastatin - tablet - 20mg - lovastatin 20mg - hmg-coa reductase inhibitors